Daily Anesthesiology Research Analysis
Analyzed 85 papers and selected 3 impactful papers.
Summary
Today’s top anesthesiology/critical care papers include: a multicenter double-blind RCT showing suvorexant does not improve early postoperative sleep or reduce delirium after cardiac surgery; a double-blind RCT demonstrating oliceridine yields similar analgesia but substantially less PONV than sufentanil in thyroid surgery; and a pilot ICU study establishing bedside confocal laser endomicroscopy as a feasible, safe tool that reveals alveolar micro-architecture beyond chest CT in ARDS.
Research Themes
- Postoperative sleep and delirium management after cardiac surgery
- Biased mu-opioid agonists to reduce PONV while maintaining analgesia
- Bedside microscopic lung imaging in ARDS (diagnostic innovation)
Selected Articles
1. Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial.
In a two-center, double-blind RCT of 100 adults after cardiac surgery, suvorexant did not reduce wakefulness after sleep onset, increase total sleep time, or improve subjective sleep quality versus placebo. Rescue sedative use, delirium incidence, and delirium-free days were also similar between groups.
Impact: This high-quality RCT provides definitive negative evidence against routine suvorexant use for early postoperative sleep or delirium prevention after cardiac surgery.
Clinical Implications: Routine suvorexant administration after cardiac surgery in ICU patients should not be expected to improve sleep architecture or reduce delirium; nonpharmacologic sleep promotion and alternative strategies remain priorities.
Key Findings
- No reduction in wakefulness after sleep onset (primary endpoint) with suvorexant versus placebo.
- Total sleep time and subjective sleep quality were not improved by suvorexant.
- No differences in delirium incidence, delirium-free days, or rescue sedative use between groups.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled design
- Objective EEG-based sleep staging with blinded scoring and prospective delirium assessments
Limitations
- Modest sample size and limited to two academic ICUs
- Intervention initiated post-extubation; results may not generalize to different timing or dosing regimens
Future Directions: Evaluate timing, dosing, and combination with nonpharmacologic sleep strategies; compare other orexin antagonists; explore patient subgroups at higher delirium risk.
BACKGROUND: Patients recovering from cardiac surgery in the intensive care unit (ICU) do not sleep well. Commonly used sedative-hypnotic medications can disrupt sleep architecture and increase the risk of delirium in critically ill patients after surgery. The orexin receptor antagonist suvorexant, improves sleep onset and duration in patients with chronic insomnia. We hypothesized that suvorexant improves sleep onset and duration while also reducing the incidence of delirium after cardiac surgery. METHODS: This multicentric, double-blind, randomized controlled trial was conducted at two university-based cardiac ICUs. One hundred adult patients were enrolled after admission to the ICU following cardiac surgery. Enrollment occurred between March 2020 and February 2025. Participants were randomized to receive either a once daily oral dose of suvorexant 20 mg or placebo. Treatment began on the first night after extubation and continued until hospital discharge or for a maximum of seven days, whichever occurred first. Sleep was recorded using an electroencephalography (EEG) monitor (SedLine, Masimo Corp., California, USA) on the first night after extubation and was scored blindly by an experienced registered polysomnographic technologist. The primary outcome was wakefulness after persistent sleep onset (WASO). Sleep onset was defined as the first 30-second epoch classified by rapid eye movement (REM) or non-REM stages 1, 2, 3 after lights off. Wakefulness was defined as an awake period of 30s or longer. Sleep questionnaires were administered and delirium screenings were conducted every morning until hospital discharge.
2. Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
In 232 thyroid surgery patients, oliceridine significantly reduced 48-hour PONV incidence (12% vs 28%; OR 0.35) compared with sufentanil while providing adequate analgesia. Secondary measures (severity, rescue antiemetics, recovery quality) favored oliceridine without safety signal.
Impact: Demonstrates a clinically meaningful reduction in PONV with a biased μ-agonist while maintaining analgesia, supporting opioid selection strategies that improve recovery quality.
Clinical Implications: For low-risk thyroid surgery patients, oliceridine may be preferred over sufentanil to reduce PONV without compromising analgesia; confirmation in broader and higher-risk surgeries is warranted.
Key Findings
- Oliceridine reduced 48-hour PONV incidence versus sufentanil (12% vs 28%; OR 0.35, 95% CI 0.17–0.72).
- Analgesic efficacy was adequate and comparable between groups.
- Secondary outcomes (PONV severity, rescue antiemetic use, recovery quality) generally favored oliceridine.
Methodological Strengths
- Prospective, double-blind, randomized controlled design with adequate sample size
- Clinically relevant primary endpoint (48-hour PONV) and multiple recovery-focused secondary outcomes
Limitations
- Population limited to relatively young ASA I–II thyroidectomy patients, potentially limiting generalizability
- Details on dosing paradigms and multimodal antiemetic prophylaxis were not fully elaborated in the abstract
Future Directions: Replicate findings in higher-risk and more invasive surgeries, and evaluate ERAS-aligned multimodal regimens integrating oliceridine.
PURPOSE: Postoperative nausea and vomiting (PONV) is a common complication following thyroid surgery, often exacerbated by opioid use. Oliceridine, a novel G protein-biased μ-opioid receptor agonist, may reduce opioid-related adverse events. This study aimed to compare the impact of oliceridine versus sufentanil on the incidence and severity of PONV in patients undergoing thyroid surgery. PATIENTS AND METHODS: In this prospective, double-blind, randomised controlled trial conducted between May 2025 and February 2026, 232 patients scheduled for thyroid surgery were randomly assigned to receive either oliceridine or sufentanil for intraoperative analgesia. The primary outcome was the incidence of PONV during the first 48 h postoperatively. Secondary outcomes included PONV severity, need for rescue anti-emetics, postoperative pain scores, recovery quality, and other adverse events. RESULTS: The incidence of PONV within 48 h postoperatively was significantly lower in the oliceridine group [13/107 (12%)] compared with the sufentanil group [31/110 (28%)] (OR = 0.35, 95% CI: 0.17-0.72, CONCLUSION: For young ASA I-II patients undergoing thyroid surgery, oliceridine yields adequate postoperative analgesia and lower PONV rates versus sufentanil. Additional trials involving high-intensity surgical procedures are needed to confirm consistent equivalence.
3. Confocal laser endomicroscopy in patients with acute respiratory failure.
In 33 mechanically ventilated ICU patients (41 procedures), bedside bronchoscopic CLE achieved 100% procedural feasibility with no CLE-related adverse events. CLE identified distinct patterns of alveolar filling (air, fluid, cells) and architecture; it detected abnormalities in most CT-normal segments and showed architectural changes in segments with ground-glass opacities. Ex vivo CLE findings matched histopathology in an autopsy case.
Impact: Demonstrates real-time, alveolar-level imaging beyond CT in ventilated ARDS patients, opening avenues for bedside phenotyping of early microstructural remodeling.
Clinical Implications: CLE may complement CT by revealing microscopic alveolar filling and architectural changes, potentially informing diagnosis, phenotyping, and timing of antifibrotic or ventilatory strategies in ARDS.
Key Findings
- Procedural feasibility was 100% (≥1 interpretable alveolar video per procedure) with no CLE-related adverse events.
- CLE characterized alveolar filling (air 63%, fluid 12%, cells 25%) and architecture (thin elastin fibers 25%, increased elastin with preserved architecture 53%, distorted architecture 19%).
- CLE detected abnormalities in 6/7 CT-normal segments and showed architectural changes in 60/78 segments with ground-glass opacities; ex vivo CLE was concordant with histopathology.
Methodological Strengths
- Prospective bedside imaging with predefined feasibility and safety endpoints
- Multiple segment sampling and qualitative CT–CLE correlation; ex vivo histopathologic concordance
Limitations
- Single-center observational pilot with limited sample size and qualitative comparisons
- No definitive linkage to patient-centered outcomes or interventional decision-making
Future Directions: Standardize CLE acquisition/interpretation, quantify image biomarkers, and test whether CLE-guided phenotyping improves ARDS management and outcomes.
BACKGROUND: Survivors of the early exudative phase of acute respiratory distress syndrome (ARDS) may develop a fibroproliferative repair response and persistent microstructural remodeling associated with adverse outcomes. Conventional imaging, including chest computed tomography (CT), has limited biological specificity for early microscopic remodeling. Confocal laser endomicroscopy (CLE) enables real-time bronchoscopic imaging of the alveolar compartment with near-histologic resolution. We evaluated the feasibility and safety of bedside bronchoscopic CLE in invasively ventilated ICU patients with acute respiratory failure and explored whether in vivo CLE provides microscopic alveolar information complementary to chest CT. METHODS: In this single-center observational pilot study, mechanically ventilated adult ICU patients with a clinical indication for bronchoalveolar lavage (BAL) underwent additional bedside bronchoscopic CLE. Primary endpoints were feasibility (≥ 1 interpretable alveolar video with visible septal architecture per procedure) and safety (CLE-related adverse events within 24 h). Secondary exploratory endpoints were dominant in vivo CLE patterns of alveolar filling (air, fluid, cells) and architecture (thin elastin fibers with hexagonal architecture; increased elastin with preserved architecture; increased elastin with distortion) and qualitative comparison with CT abnormalities in the imaged segments. As an exploratory additional analysis, ex vivo CLE was performed in a single autopsy case and compared with histopathology.